Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinical improvements across anxiety, depression, insomnia and quality of life

Data to be presented include 77.8% anxiety response rate at end of treatment, durable benefits maintained at 8-week follow-up and no serious adverse events, seizures or manic/hypomanic switches reported

Presentations of clinical data further strengthen the scientific viability of Nexalin's new proprietary non-invasive approach to deep-brain frequency-based neurostimulation as the Company prepares for global commercial initiatives

HOUSTON, TX, June 16, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that two clinical abstracts evaluating Nexalin's proprietary DIFS™ 15 mA, 77.5 Hz treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference.

The accepted abstracts are titled:

  1. "Transcranial Alternating Current Stimulation for the Treatment of Anxiety: Preliminary Results from an Open-Label Pilot Clinical Trial"
  2. "Transcranial Alternating Current Stimulation for Comorbid Anxiety and Insomnia: Preliminary Findings on Insomnia and Quality of Life from an Open-Label Pilot Trial"

The accepted abstracts are based on data from the Company's recently completed 8-week, single-center, prospective, clinical trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo. Adults with generalized anxiety disorder and comorbid insomnia received 20 sessions of Nexalin's proprietary 15 mAmp deep-brain  frequency stimulation over four weeks, followed by a four-week follow-up period. Each 40-minute session was administered using the Nexalin DIFS™ device at 15 mA and 77.5 Hz.